The Pharmacological Treatment of Tricyclic-Resistant Depression: Review and Management Guidelines

References

• Akiskal H. S. A proposed clinical approach to chronic and ‘resistant’ depressions: evaluation and management. Journal of Clinical Psychiatry 1985; 46: 32–6
   PubMed Web of Science ®Google Scholar
• Angst J., Woggon B., Schoepf J. The treatment of depression with 1–5-hydroxytryptophan versus imipramine. Archiv Fur Psychiatrie und Nervenkrankheiten 1977; 224: 175–86
   PubMedGoogle Scholar
• Antonucco D. O., Akins W. T., Chatham P. M., et al. An exploratory study: the psychoeducational group treatment of drug-refractory unipolar depression. Journal of Behaviour Therapy and Experimental Psychology 1984; 15: 309–13
   PubMedGoogle Scholar
• Apa Task Force. Tricyclic antidepressants — blood level measurements and clinical outcome: an APA task force report. American Journal of Psychiatry 1985; 142: 155–62
   PubMed Web of Science ®Google Scholar
• Ayd F. J., Jr. Treatment-resistant depression. International Drug Therapy Newsletter 1983; 18: 25–7
   Google Scholar
• Ayuso Gutierrez J. L., Lopez-Ibor Alino J. J. Tryptophan and an Maoi (nialamide) in the treatment of depression: a double-blind study. International Pharmacopsychiatry 1971; 6: 92–7
   PubMedGoogle Scholar
• Banki C. M. Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women. European Journal of Clinical Pharmacology 1977; 11: 311–15
   PubMed Web of Science ®Google Scholar
• Barker W. A., Eccleston D. The treatment of chronic depression: an illustrative case. British Journal of Psychiatry 1984; 144: 317–19
   PubMedGoogle Scholar
• Bartlett J., Bridges P., Kelly D. Contemporary indications for psychosurgery. British Journal of Psychiatry 1981; 138: 507–11
   PubMed Web of Science ®Google Scholar
• Belmaker R. H., Lerer B., Zohar J. Salbutamol treatment of depression. Typical and Atypical Antidepressants: Clinical Practice, E. Costa, G. Racagni. Raven Press, New York 1982; 181–94
   Google Scholar
• Bielski R. J., Friedel R. O. Prediction of tricyclic antidepressant response: a critical review. Archives of General Psychiatry 1976; 33: 1479–89
   PubMed Web of Science ®Google Scholar
• Blier P., De Montigny C. Short-term lithium administration cnhances serotonergic neurotransmission: electrophysiological evidence in the rat CNS. European Journal of Pharmacology 1985; 113: 69–77
   PubMedGoogle Scholar
• Broadhurst A. D. L-tryptophan versus ECT. Lancet 1970; 1392–3, 1
   PubMedGoogle Scholar
• Charney D. S., Price L. M., Heninger G. Desipramine-yohimbine combination treatment of refractory depression. Archives of General Psychiatry 1986; 43: 1155–61
   PubMedGoogle Scholar
• Chou Inard G., Young S. N., Annable L., Sourkes T. L. Tryptophan-nicotinamide, imipramine and their combination in depression: a controlled study. Acta Psychiatrica Scandinavica 1979; 59: 395–414
   PubMedGoogle Scholar
• Coppen A., Shaw D. A., Farrell J. P. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1963; 79–81, 1
   PubMedGoogle Scholar
• Davidson J., McLeod M., Law-Yone B., Linnoila M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Archives of General Psychiatry 1978; 35: 639–42
   PubMed Web of Science ®Google Scholar
• De Montigny C., Grundberg F., Mayer A., Deschenes J. P. Lithium induces rapid relief of depression in tricyclic and antidepressant drug non-responders. British Journal of Psychiatry 1981; 138: 252–6
   PubMed Web of Science ®Google Scholar
• De Montigny C., Cournoyer G., Morrisett R., Langlois R. Lithium carbonate addition in tricyclic antidepressant-resistant depression. Archives of General Psychiatry 1983; 40: 1327–34
   PubMed Web of Science ®Google Scholar
• De Montigny C., Elie R., Caille G. Rapid response to the addition of lithium in iprindole-resistant unipolar depression: a pilot study. American Journal of Psychiatry 1985; 142: 220–3
   PubMed Web of Science ®Google Scholar
• Dessauer M., Goetze U., Tolle R. Periodic sleep deprivation in drug-refractory depression. Neuropsychobiology 1985; 13: 111–16
   PubMed Web of Science ®Google Scholar
• Earle B. V. Thyroid hormone and tricyclic antidepressants in resistant depressions. American Journal of Psychiatry 1970; 126: 1667–9
   PubMed Web of Science ®Google Scholar
• Extein I., Gold M. S., Pottash A. L. C. Psychopharmacologic treatment of depression. Psychiatric Clinics of North America 1984; 7: 503–17
   PubMedGoogle Scholar
• Fennell M. J. V., Teasdale J. D. Cognitive therapy with chronic, drug-refractory depression outpatients: a note of caution. Cognitive Therapy and Research 1982; 6: 455–60
   Google Scholar
• Freyhan F. A. Contributions to the definition of therapy-resistance and of the therapy-resistant depressions. Pharmacopsychiatrica 1974; 7: 70–5
   Google Scholar
• Fuller R. W. Drugs altering serotonin synthesis and metabolism. Neuropharmacology of Serotonin, A. R. Green. Oxford University Press, Oxford 1985; 1–20
   Google Scholar
• Gander D. R. Treatment of depressive illnesses with combined antidepressants. Lancet 1965; 107–9, 2
   PubMedGoogle Scholar
• Garbutt J. C., Mayo J. P., Gillette G. M., et al. Lithium potentiation of tricyclic antidepressants following lack of T3potentiation. American Journal of Psychiatry 1986; 143: 1038–9
   PubMed Web of Science ®Google Scholar
• Georgotas A., Friedman E., McCarthy M., et al. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biological Psychiatry 1983; 18: 195–205
   PubMedGoogle Scholar
• Gerner R. H. Systematic treatment approach to depression and treatment resistant depression. Psychiatric Annals 1983; 13: 37–49
   Web of Science ®Google Scholar
• Glassman A. H., Platman S. R. Potentiation of a monoamine oxidase inhibitor by tryptophan. Journal of Psychiatric Research 1969; 7: 83–8
   PubMed Web of Science ®Google Scholar
• Goodwin F. K., Prange A. J., Post R. M., et al. Potentiation of antidepressant effects by l-triiodothyronine in tricyclic nonresponders. American Journal of Psychiatry 1982; 139: 34–8
   PubMed Web of Science ®Google Scholar
• Hafner R. J. Marriage and affective disorders. Marriage and Mental Illness: A Sex Roles Perspective, R. J. Hafner. Guilford, New York 1986; 122–51
   Google Scholar
• Haskovec L. The action of reserpine on imipramine-resistant depressive patients: Clinical and biochemical study. Psychopharmacologia 1967; 11: 18–30
   PubMedGoogle Scholar
• Heninger G., Charney D. S., Sternberg D. E. Lithium carbonate augmentation of antidepressant treatment. Archives of General Psychiatry 1983; 40: 1335–42
   PubMed Web of Science ®Google Scholar
• Himmelhoch J. M., Petre T., Kupfer D. J., et al. Treatment of previously intractable depressions with tranylcypromine and lithium. Journal of Nervous and Mental Disease 1972; 155: 216–20
   PubMed Web of Science ®Google Scholar
• Himmelhoch J. M., Fuchs C. Z., Symons B. J. A double-blind study of tranyleypromine treatment of major anergic depression. Journal of Nervous and Mental Disease 1982; 170: 628–34
   PubMedGoogle Scholar
• Hopkinson G., Kenny F. Treatment with reserpine of patients resistant to tricyclic antidepressants: a double-blind trial. Psychiatric Clinics 1975; 8: 109–14
   PubMedGoogle Scholar
• Kantor D., McNeven S., Leichner P., et al. The benefit of lithium carbonate adjunct in refractory depression — fact or fiction?;?;. Canadian Journal of Psychiatry 1986; 31: 416–18
   PubMedGoogle Scholar
• Katona C. L. E., Barnes T. R. E. Pharmacological strategies in depression. British Journal of Hospital Medicine 1985; 34: 168–71
   PubMedGoogle Scholar
• Keller M., Klerman G., Lavori P. W., et al. Long-term outcome of episodes of major depression. Journal of the American Medical Association 1984; 252: 788–92
   PubMed Web of Science ®Google Scholar
• Keller M., Lavori P. W., Rice J., et al. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. American Journal of Psychiatry 1986; 143: 24–8
   PubMed Web of Science ®Google Scholar
• Kielholz P. Latest findings in the treatment of depression. New Results in Depression Research, G. L. Klerman, N. Matussek. Springer-Verlag, Berlin 1986; 99–111
   Google Scholar
• Kiloh L. G., Ball J. R. B., Garside R. F. Prognostic factors in treatment of depressive states with imipramine. British Medical Journal 1962; 1: 1225–7
   PubMed Web of Science ®Google Scholar
• Klaiber E. L., Broverman D. M., Vogel W., Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Archives of General Psychiatry 1979; 36: 550–4
   PubMed Web of Science ®Google Scholar
• Kline N., Sacks W. Treatment of depression with an MAO inhibitor followed by 5-HTP — an unfinished research project. Acta Psychiatrica Scandinavica 1980; 233–41, suppl. 280
   PubMedGoogle Scholar
• Kupfer D. J., Spiker D. G. Refractory depression: prediction of non-response by clinical indicators. Journal of Clinical Psychiatry 1981; 42: 307–12
   PubMed Web of Science ®Google Scholar
• Lader M. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. Journal of Clinical Psychiatry 1983; 44: 20–4
   PubMed Web of Science ®Google Scholar
• Lopez-Ibor Alino J.J., Ayuso Gutierrez J.L., Iglesias M. L. M. Tryptophan and amitriptyline in the treatment of depression: a double-blind study. International Pharmacopsychiatrie 1973; 8: 145–51
   Google Scholar
• Louie A. K., Meltzer H. Y. Lithium potentiation of antidepressant treatment. Journal of Clinical Psychopharmacology 1984; 4: 316–21
   PubMed Web of Science ®Google Scholar
• McGrath P. J., Stewart J. W., Harrison W., Stewart J. W. Phenelzine treatment of melancholia. Journal of Clinical Psychiatry 1986; 47: 420–2
   PubMed Web of Science ®Google Scholar
• Mendels J., Ramsey T. A., Dyson W. L., Frazer A. Lithium as an antidepressant. Archives of General Psychiatry 1979; 36: 845–6
   PubMed Web of Science ®Google Scholar
• Moscovich D., Mester R. Tricyclic antidepressive treatment reinforced by reserpine. Israel Journal of Psychiatry and Related Sciences 1984; 21: 283–9
   PubMedGoogle Scholar
• Mrc. Clinical trial of the treatment of depressive illness. British Medical Journal 1965; 881–6, 1
   PubMedGoogle Scholar
• Nelson J. C., Byck R. Rapid response to lithium in phenelzine nonresponders. British Journal of Psychiatry 1982; 141: 85–6
   PubMed Web of Science ®Google Scholar
• Nelson J. C., Mazure C. M. Lithium augmentation in psychotic depression refractory to combined drug treatment. American Journal of Psychiatry 1986; 143: 363–6
   PubMed Web of Science ®Google Scholar
• Neubauer H., Bermingham P. A depressive syndrome responsive to lithium. Journal of Nervous and Mental Disease 1976; 163: 276–81
   PubMedGoogle Scholar
• Nolen W. A., Van De Putte J. J., Dijken W. A., Kamp J. S. L-5HTP in depression resistant to re-uptake inhibitors: an open comparative study with tranylcypromine. British Journal of Psychiatry 1985; 147: 16–22
   PubMed Web of Science ®Google Scholar
• Ogura C., Okuma T., Uchida Y., et al. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states. Folia Psychiatrica et Neurologica Japonica 1974; 28: 179–86
   PubMedGoogle Scholar
• Paul S. M., Extein I., Calil H. M., et al. Use of ECT with treatment-resistant depressed patients at the National Institute of Mental Health. American Journal of Psychiatry 1981; 138: 486–9
   PubMedGoogle Scholar
• Paykel E. S. How effective are antidepressants?;. Psychopharmacology: Recent Advances and Future Prospects, S. D. Iversen. Oxford University Press, Oxford 1985; 3–13
   Google Scholar
• Poldinger W. Combined administration of desipramine and reserpine or tetrabenazine in depressive patients. Psychopharmacologia 1963; 4: 308–10
   PubMedGoogle Scholar
• Pope H. G., Jonas J. M., Hudson J. I., Kafka M. P. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. American Journal of Psychiatry 1985; 142: 491–2
   PubMed Web of Science ®Google Scholar
• Post R. M., Uhde T. W., Roy-Byrne P. P., Joffe R. T. Antidepressant effects of carbamazcpine. American Journal of Psychiatry 1986; 143: 29–34
   PubMed Web of Science ®Google Scholar
• Potter W. Z., Scheinin M., Golden R. N., et al. Selective antidepressants and cerebrospinal fluid. Archives of General Psychiatry 1985; 42: 1171–80
   PubMedGoogle Scholar
• Prange A. J., Wilson I. C., Rabon A. M., Lipton M. A. Enhancement of imipramine antidepressant activity by thyroid hormone. American Journal of Psychiatry 1969; 126: 457–69
   PubMed Web of Science ®Google Scholar
• Prange A. J., Wilson I. C., Knox A., et al. Enhancement of imipramine by thyroid stimulating hormone: clinical and theoretical implications. American Journal of Psychiatry 1970; 127: 191–9
   PubMed Web of Science ®Google Scholar
• Prasad A. J. Efficacy of carbamazepine as an antidepressant in chronic resistant depressives. Journal of the Indian Medical Association 1985; 83: 235–7
   PubMedGoogle Scholar
• Price L. H., Conwell Y., Nelson J. C. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. American Journal of Psychiatry 1983; 140: 318–22
   PubMed Web of Science ®Google Scholar
• Price L. H., Charney D. S., Heninger G. R. Efficacy of lithium-tranylcypromine treatment in refractory depression. American Journal of Psychiatry 1985; 142: 619–23
   PubMed Web of Science ®Google Scholar
• Price L. H., Charney D. S., Heninger G. R. Variability of response to lithium augmentation in refractory depression. American Journal of Psychiatry 1986; 143: 1387–93
   PubMed Web of Science ®Google Scholar
• Quality Assurance Project. A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry 1983; 17: 129–48
   PubMed Web of Science ®Google Scholar
• Quitkin F. M. The importance of dosage in prescribing antidepressants. British Journal of Psychiatry 1985; 147: 593–7
   PubMed Web of Science ®Google Scholar
• Quitkin F. M., Rabkin J. G., Ross D., McGrath P. J. Duration of antidepressant drug treatment. Archives of General Psychiatry 1984; 41: 238–45
   PubMed Web of Science ®Google Scholar
• Razani J., White K. L., White J., et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. Archives of General Psychiatry 1983; 40: 657–61
   PubMed Web of Science ®Google Scholar
• Roos B. E. Tryptophan, 5-hydroxytrypiophan and tricyclic antidepressants in the treatment of depression. Monographs in Neural Sciences 1976; 3: 23–5
   PubMedGoogle Scholar
• Sargant W. Drugs in the treatment of depression. British Medical Journal 1961; 225–7, 1
   PubMedGoogle Scholar
• Schmauss M., Laakmann G., Dieterle P. Yohimbine in combination with tricyclic antidepressants in the treatment of therapy-resistant depressed patients. Pharmacopsychiatry 1986; 19: 264–5
   Google Scholar
• Schwarcz G., Halaris A., Baxter L., et al. Normal thyroid function in desipramine nonresponders converted to responders by the addition of l-triiodothyronine. American Journal of Psychiatry 1984; 141: 1614–16
   PubMed Web of Science ®Google Scholar
• Sethna E. R. A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment. British Journal of Psychiatry 1974; 124: 265–72
   PubMed Web of Science ®Google Scholar
• Shapira B., Oppenheim G., Zohar J., et al. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biological Psychiatry 1985; 20: 570–83
   PubMedGoogle Scholar
• Shaw D. M. The practical management of affective disorders. British Journal of Psychiatry 1977; 130: 432–51
   PubMed Web of Science ®Google Scholar
• Shaw D. M., Macsweeney D. A., Hewland R., Johnson L. Tricyclic antidepressants and tryptophan in unipolar depression. Psychological Medicine 1975; 5: 276–8
   PubMedGoogle Scholar
• Simpson G. M., Lee J. M., Cuculica A., Kellner R. Two dosages of imipramine in hospitalised endogenous and neurotic depressives. Archives of General Psychiatry 1976; 33: 1093–102
   PubMedGoogle Scholar
• Stern S. L., Mendels J. Drug combinations in the treatment of refractory depression: a review. Journal of Clinical Psychiatry 1981; 42: 368–73
   PubMed Web of Science ®Google Scholar
• Stewart J. W., McGrath P. J., Liebowitz M. R., et al. Treatment outcome validation of DSM-III depressive subtypes. Archives of General Psychiatry 1985; 42: 1148–53
   PubMedGoogle Scholar
• Targum S. D., Greenberg R. J., Harmon R. L., et al. Thyroid hormone and the TRH stimulation test in refractory depression. Journal of Clinical Psychiatry 1984; 45: 345–6
   PubMed Web of Science ®Google Scholar
• Thomson J., Rankin H., Ashcroft G. W., et al. The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychological Medicine 1982; 12: 741–52
   PubMed Web of Science ®Google Scholar
• Tsutsui S., Yamazaki Y., Namba T., Tsushima M. Combined therapy of T3and antidepressants in depression. Journal of International Medical Research 1979; 7: 138–46
   PubMed Web of Science ®Google Scholar
• Van Hiele L. J. 1–5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry?;?;. Neuropsychobiology 1980; 6: 230–40
   PubMed Web of Science ®Google Scholar
• Van Praag H. M., Van Den Burg W., Bos E. R. H., Dols L. C. W. 5-hydroxytryptophan in combination with clomipramine in ‘therapy-resistant’ depressions. Psychopharmacologia 1974; 38: 267–9
   PubMedGoogle Scholar
• Walinder J., Skott A., Carlsson A., Nagy A. Potentiation of the antidepressant action of clomipramine by tryptophan. Archives of General Psychiatry 1976; 33: 1384–9
   PubMed Web of Science ®Google Scholar
• Walinder J., Carlsson A., Persson R. 5-HT reuptake inhibitors plus tryptophan in endogenous depression. Acta Psychiatrica Scandinavica 1981; 179–90, suppl. 290
   Google Scholar
• Watt D. C., Crammer J. L., Elkes A. Metabolism, anticholinergic effects and therapeutic effects on outcome of desmethylimipramine in depressive illness. Psychological Medicine 1972; 2: 397–405
   PubMed Web of Science ®Google Scholar
• Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. The Pharmacological Basis of Therapeutics, 7th edn, A. G. Gillman, L. S. Goodman, T. W. Roll. McMillan, New York 1985; 207–10
   Google Scholar
• Weissman M. M., Akiskal H. S. The role of psychotherapy in chronic depressions: a proposal. Comprehensive Psychiatry 1984; 25: 23–31
   PubMedGoogle Scholar
• Wharton R. N., Perel J. M., Dayton P. G., Malitz S. A potential clinical use for methylphenidate with tricyclic antidepressants. American Journal of Psychiatry 1971; 127: 1619–25
   PubMed Web of Science ®Google Scholar
• White K., Pistole T., Boyd J. L. Combined monoamine oxidase inhibitor — tricyclic antidepressant treatment: a pilot study. American Journal of Psychiatry 1980; 137: 1422–5
   PubMedGoogle Scholar
• White K., Simpson G. Combined MaoI-tricyclic antidepressant treatment. A revaluation. Journal of Clinical Psychopharmacology 1981; 1: 264–82
   PubMed Web of Science ®Google Scholar
• Whybrow P. C., Prange A. J. A hypothesis of thyroid-catecholamine-receptor interaction. Archives of General Psychiatry 1981; 38: 106–13
   PubMed Web of Science ®Google Scholar
• Willner P. Serotonin and depression: clinical studies. Depression: A Psychobiological Synthesis, P. Willner. John Wiley, New York 1985; 307–26
   Google Scholar
• Winston F. Combined antidepressant treatment. British Journal of Psychiatry 1971; 118: 301–4
   PubMed Web of Science ®Google Scholar
• Young J. P. R., Lader M. H., Hughes M. C. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. British Medical Journal 1979; 2: 1315–17
   PubMed Web of Science ®Google Scholar